Since it has been shown that CpG methylation can inactivate promoter function, leading to inhibition of hPer gene promoter function in breast and endometrial carcinoma, whether CpG methylation on the PER2 promoter contributes to human colorectal cancer development needs further investigation. This evidence concerns the gene PER2 and colorectal cancer.